Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 10, 2025 08:00 ET | Source: Avalyn Pharma Inc.

Avalyn to Participate in Upcoming Investor Conference in April

CAMBRIDGE, Mass., April 10, 2025 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc., a clinical-stage biopharmaceutical company focused on development of inhaled therapies for the treatment of life-threatening...
April 01, 2025 08:00 ET | Source: Avalyn Pharma Inc.

Avalyn Completes Successful Phase 1 Clinical Trials of AP02, its Novel Inhaled Formulation of Nintedanib, Preparing for Phase 2 Development in Idiopathic Pulmonary Fibrosis

Topline data from the single- and multiple-ascending dose studies confirmed safety and favorable tolerability profile of AP02 at all dose levels Full safety, tolerability, and pharmacokinetics data...
February 25, 2025 08:00 ET | Source: Avalyn Pharma Inc.

Avalyn to Participate in TD Cowen 45th Annual Health Care Conference

CAMBRIDGE, Mass., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc., a clinical-stage biopharmaceutical company focused on development of inhaled therapies for the treatment of life-threatening...
December 17, 2024 08:00 ET | Source: Avalyn Pharma Inc.

Avalyn to Present at the 43rd Annual J.P. Morgan Healthcare Conference

CAMBRIDGE, Mass., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc., a clinical-stage biopharmaceutical company focused on development of inhaled therapies for the treatment of life-threatening...
November 25, 2024 08:00 ET | Source: Avalyn Pharma Inc.

Avalyn to Participate in Multiple Upcoming Investor Conferences

CAMBRIDGE, Mass., Nov. 25, 2024 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc., a clinical-stage biopharmaceutical company focused on development of inhaled therapies for the treatment of life-threatening...
November 14, 2024 08:00 ET | Source: Avalyn Pharma Inc.

Avalyn Appoints Heather Turner, J.D., Biopharma Industry Veteran, as Chair of its Board of Directors

CAMBRIDGE, Mass., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc., a clinical-stage biopharmaceutical company focused on development of inhaled therapies for the treatment of life-threatening...
November 04, 2024 08:00 ET | Source: Avalyn Pharma Inc.

Avalyn to Participate in Multiple Upcoming Investor Conferences

CAMBRIDGE, Mass., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc., a clinical-stage biopharmaceutical company focused on development of inhaled therapies for the treatment of life-threatening...
October 08, 2024 09:00 ET | Source: Avalyn Pharma Inc.

Avalyn CEO Lyn Baranowski Named a PharmaVoice 100 Honoree

CAMBRIDGE, Mass., Oct. 08, 2024 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc., a clinical-stage biopharmaceutical company focused on development of inhaled therapies for the treatment of life-threatening...
September 30, 2024 08:00 ET | Source: Avalyn Pharma Inc.

Avalyn Announces Upcoming Presentations on its Lead Program AP01, Inhaled Pirfenidone, for the Treatment of Pulmonary Fibrosis at the 22nd International Colloquium on Lung and Airway Fibrosis

CAMBRIDGE, Mass., Sept. 30, 2024 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc., a clinical-stage biopharmaceutical company focused on development of inhaled therapies for the treatment of life-threatening...
September 08, 2024 09:00 ET | Source: Avalyn Pharma Inc.

Avalyn Presents Multiple Posters on AP01 for Pulmonary Fibrosis, Including MIST Phase 2b Trial Design and ATLAS Phase 1b Study Post-hoc Analyses, at ERS 2024

Trial Design Showcased for the MIST Study, a Recently Initiated Phase 2b Clinical Trial, Evaluating the Efficacy and Safety of AP01 (inhaled pirfenidone) Compared to Placebo in Patients with...